Bliss GVS Pharma Limited has announced the appointment of two non-executive, independent directors to its board, effective April 3, 2026, for five-year terms through April 2, 2031. The appointments were approved by the board through a circular resolution following a recommendation from the Nomination and Remuneration Committee, and are to be formalized with the members’ approval via a postal ballot. The move underscores Bliss GVS’s ongoing emphasis on governance enhancements as it positions itself for the next phase of growth.
Vijayanarayanan Mahadevan brings to Bliss GVS a Chartered Accountant’s pedigree and more than three decades of finance leadership across global firms such as Alcon, Sandoz, Novartis and SHV Energy. The brief profile highlights his strength in establishing finance functions for new businesses across manufacturing, trading and R&D settings, and notes a track record of steering loss-making units toward profitability and sustainable operations. His professional footprint also includes leadership roles within the accounting community, including past presidencies and chairmanships, and he currently serves as an independent director on boards such as The Ruby Mills Limited, Marathon Nextgen Realty Limited, and Siyaram Silk Mills Limited.
Deepak Rameshchandra Shah was also appointed as an additional Non-Executive Independent Director for the same five-year term. The notice confirms that both appointments are non-executive and independent, and the disclosures state that neither appointee is related to any of Bliss GVS’s other directors. While the release highlights the governance intent behind adding two independent directors, it also leaves room for the market to learn more about Mr. Shah’s professional background as he begins his tenure on Bliss GVS’s board.
Together, the appointments broaden the board’s mix of governance and financial oversight capabilities, signaling Bliss GVS’s intent to reinforce strategic direction, risk management, and financial discipline as it pursues its growth agenda.